inotuzumab ozogamicin
Selected indexed studies
- Inotuzumab Ozogamicin. (, 2012) [PMID:31643242]
- Inotuzumab Ozogamicin. (, 2006) [PMID:29999985]
- Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. (Lancet Haematol, 2023) [PMID:37187201]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Inotuzumab Ozogamicin. (2012) pubmed
- Inotuzumab Ozogamicin. (2006) pubmed
- Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. (2023) pubmed
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. (2016) pubmed
- Inotuzumab Ozogamicin: First Pediatric Approval. (2024) pubmed
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. (2019) pubmed
- Inotuzumab Ozogamicin as First-Line Therapy in Acute Lymphoblastic Leukemia. (2025) pubmed
- Inotuzumab Ozogamicin: First Global Approval. (2017) pubmed
- Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL. (2024) pubmed
- Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. (2018) pubmed